Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases

Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.

Sensorineural Hearing Loss (SNHL)

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322 Phase 2b - 208 Study

Stage: Phase 2

Study of noise induced and sudden SNHL patients, ages 18 – 65.
Study enrolling 124 subjects, first subject dosed October 2021

FX-322 Phase 1b – 111 Study

Stage: Phase 1

Open-label safety study focused on administration conditions for FX-322. Subjects had mild to severe SNHL, ages 18 – 65
Study enrolled with 33 subjects, completed March 2021. Extension phase ongoing.

FX-322 Phase 1b – 112 Study

Stage: Phase 1

Study of mild to moderately severe age-related hearing loss patients, ages 66 – 85
Study enrolled with 30 subjects, completed May 2021. Extension phase ongoing.

FX-322 Phase 1b – 113 Study

Stage: Phase 1

Study of patients with severe SNHL, ages 18 – 65
Study enrolled with 31 subjects, completed December 2021. 

FX-345

Stage: Preclinical

Multiple Sclerosis

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FREQ-162

Stage: Preclinical

Clinical Trials Information

For more information on the phase 2b clinical trial for FX-322, please visit clinicaltrials.gov.

Expanded Access Policy

Learn about our expanded access policy.

Our Program for Sensorineural Hearing Loss

Advancing FX-322 into a Phase 2b clinical study for the most common form of hearing loss

Learn More

Our Program for Multiple Sclerosis

Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosis

Learn More